Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio prioritisation”.

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

While MFN will see US drug prices reduced to match other countries, by them increasing elsewhere and using alternative models, it is unlikely that R&D will be heavily impacted. Image credit: ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

Johnson & Johnson’s pipeline IL-23 blocker, icotrokinra, has met its primary endpoint in a Phase IIb study in ulcerative colitis, meaning the drug’s efficacy and safety will now be explored in the ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

Eli Lilly announced the data from the OLE trial of Omvoh at United European Gastroenterology (UEG) Week in Berlin. Image credit: hapabapa / iStock Editorial via Getty Images Eli Lilly’s Omvoh ...

Skye Biosciences pipeline obesity drug, nimacimab, has failed to trigger significant weight loss as a monotherapy in a proof-of-concept Phase IIa trial. Image credit: Yellow_man / Shutterstock.com ...